Thompson Siegel & Walmsley LLC cut its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 12.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 534,895 shares of the medical research company’s stock after selling 72,802 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.53% of Laboratory Corporation of America Holdings worth $82,449,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. CFO4Life Group LLC bought a new stake in shares of Laboratory Corporation of America Holdings during the first quarter worth approximately $312,000. Oxford Asset Management raised its stake in shares of Laboratory Corporation of America Holdings by 68.6% in the first quarter. Oxford Asset Management now owns 51,622 shares of the medical research company’s stock worth $7,406,000 after buying an additional 21,003 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Laboratory Corporation of America Holdings by 2.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,900 shares of the medical research company’s stock worth $1,420,000 after buying an additional 199 shares in the last quarter. Elkfork Partners LLC raised its stake in shares of Laboratory Corporation of America Holdings by 2.4% in the first quarter. Elkfork Partners LLC now owns 12,936 shares of the medical research company’s stock worth $1,856,000 after buying an additional 308 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of Laboratory Corporation of America Holdings by 55.5% in the first quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock worth $3,961,000 after buying an additional 9,857 shares in the last quarter. 93.19% of the stock is currently owned by institutional investors and hedge funds.

Shares of Laboratory Corporation of America Holdings (LH) traded up 0.47% on Friday, hitting $157.61. 553,480 shares of the stock traded hands. The stock has a market cap of $16.04 billion, a PE ratio of 22.07 and a beta of 0.94. The stock has a 50 day moving average of $156.48 and a 200-day moving average of $146.53. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.36 earnings per share. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.51 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/thompson-siegel-walmsley-llc-has-82-45-million-stake-in-laboratory-corporation-of-america-holdings-lh/1538248.html.

A number of equities research analysts have commented on LH shares. Credit Suisse Group reissued a “buy” rating and set a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a report on Sunday, May 28th. ValuEngine lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Saturday, June 3rd. BidaskClub lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Barclays PLC reissued an “overweight” rating and set a $182.00 price objective (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday, July 17th. Finally, Craig Hallum reissued a “buy” rating and set a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings currently has a consensus rating of “Buy” and a consensus target price of $159.75.

In other news, insider Lisa J. Uthgenannt sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total transaction of $800,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 3,100 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $156.88, for a total value of $486,328.00. Following the sale, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 45,568 shares of company stock worth $7,127,415. Company insiders own 0.90% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.